NO20091190L - Fremgangsmater og sammensetninger for behandling av kreft - Google Patents

Fremgangsmater og sammensetninger for behandling av kreft

Info

Publication number
NO20091190L
NO20091190L NO20091190A NO20091190A NO20091190L NO 20091190 L NO20091190 L NO 20091190L NO 20091190 A NO20091190 A NO 20091190A NO 20091190 A NO20091190 A NO 20091190A NO 20091190 L NO20091190 L NO 20091190L
Authority
NO
Norway
Prior art keywords
cancer
methods
compositions
treatment
hydroxylase
Prior art date
Application number
NO20091190A
Other languages
English (en)
Norwegian (no)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Cougar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091190(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cougar Biotechnology Inc filed Critical Cougar Biotechnology Inc
Publication of NO20091190L publication Critical patent/NO20091190L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20091190A 2006-08-25 2009-03-20 Fremgangsmater og sammensetninger for behandling av kreft NO20091190L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
NO20091190L true NO20091190L (no) 2009-03-20

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20091190A NO20091190L (no) 2006-08-25 2009-03-20 Fremgangsmater og sammensetninger for behandling av kreft
NO20200775A NO20200775A1 (no) 2006-08-25 2020-07-01 Fremgangsmåter og sammensetninger for behandling av kreft

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20200775A NO20200775A1 (no) 2006-08-25 2020-07-01 Fremgangsmåter og sammensetninger for behandling av kreft

Country Status (20)

Country Link
EP (3) EP2478907B1 (pl)
JP (10) JP2010501575A (pl)
KR (4) KR20200125776A (pl)
CN (2) CN101528308A (pl)
AU (6) AU2007287098C1 (pl)
CA (1) CA2661422C (pl)
CY (2) CY1115477T1 (pl)
DK (2) DK2061561T3 (pl)
ES (2) ES2869343T3 (pl)
HR (2) HRP20130961T1 (pl)
HU (1) HUE054495T2 (pl)
IL (3) IL197211A0 (pl)
LT (1) LT2478907T (pl)
NO (2) NO20091190L (pl)
NZ (1) NZ597830A (pl)
PL (2) PL2061561T3 (pl)
PT (2) PT2061561E (pl)
RS (2) RS52956B (pl)
SI (2) SI2478907T1 (pl)
WO (1) WO2008024484A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2061561T3 (pl) 2006-08-25 2013-12-31 Janssen Oncology Inc Kompozycje do leczenia raka
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
SG185930A1 (en) * 2007-10-29 2012-12-28 Takeda Pharmaceutical Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
SG10201600077RA (en) 2011-01-11 2016-02-26 Glaxosmithkline Llc Combination
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
DK2945628T3 (da) * 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
EP2969227B1 (en) * 2013-03-15 2019-05-08 Iceutica Inc. Abiraterone acetate formulation
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
KR20150138268A (ko) * 2013-04-04 2015-12-09 엑셀리시스, 인코포레이티드 암을 치료하기 위한 약물 병용요법
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
RU2016116789A (ru) * 2013-10-01 2017-11-09 Новартис Аг Комбинация энзалутамида и афурезертиба для лечения рака
AU2014330779A1 (en) * 2013-10-01 2016-04-07 Novartis Ag Combination
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法
EA201992430A1 (ru) * 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
MX2022013043A (es) * 2020-04-16 2023-01-24 Tavanta Therapeutics Hungary Incorporated Metodos y composiciones para tratar el cancer de prostata.
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
AU2001243385B2 (en) * 2000-03-02 2006-11-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US8987240B2 (en) * 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
PL2061561T3 (pl) 2006-08-25 2013-12-31 Janssen Oncology Inc Kompozycje do leczenia raka

Also Published As

Publication number Publication date
CN101528308A (zh) 2009-09-09
AU2017201764A1 (en) 2017-04-06
SI2478907T1 (sl) 2021-08-31
RS62034B1 (sr) 2021-07-30
KR20200125776A (ko) 2020-11-04
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
CA2661422A1 (en) 2008-02-28
JP2018065859A (ja) 2018-04-26
ES2428634T3 (es) 2013-11-08
JP6445123B2 (ja) 2018-12-26
LT2478907T (lt) 2021-06-25
JP2015110577A (ja) 2015-06-18
EP2478907A2 (en) 2012-07-25
AU2022206696A1 (en) 2022-08-11
AU2007287098A1 (en) 2008-02-28
AU2007287098B2 (en) 2013-08-15
HUE054495T2 (hu) 2021-09-28
DK2478907T3 (da) 2021-05-25
PT2478907T (pt) 2021-05-26
HRP20130961T1 (hr) 2013-11-22
EP3804730A1 (en) 2021-04-14
JP2019059750A (ja) 2019-04-18
JP6740497B2 (ja) 2020-08-12
AU2015221447B9 (en) 2017-07-20
JP2021038252A (ja) 2021-03-11
NZ597830A (en) 2013-02-22
PT2061561E (pt) 2013-10-09
DK2061561T3 (da) 2013-10-07
CA2661422C (en) 2017-06-27
AU2007287098C1 (en) 2018-03-15
NO20200775A1 (no) 2009-03-20
KR20090059126A (ko) 2009-06-10
IL197211A0 (en) 2009-12-24
EP2061561A1 (en) 2009-05-27
JP2010501575A (ja) 2010-01-21
KR20150108946A (ko) 2015-09-30
CY1124221T1 (el) 2022-05-27
EP2478907B1 (en) 2021-04-14
JP2012082215A (ja) 2012-04-26
JP2024164147A (ja) 2024-11-26
JP2020114851A (ja) 2020-07-30
PL2061561T3 (pl) 2013-12-31
AU2018271331A1 (en) 2018-12-20
ES2869343T3 (es) 2021-10-25
SI2061561T1 (sl) 2013-11-29
KR20180003636A (ko) 2018-01-09
IL227746A0 (en) 2013-09-30
HRP20210670T1 (hr) 2021-06-11
AU2015221447B2 (en) 2016-12-15
CY1115477T1 (el) 2017-01-04
EP2478907A3 (en) 2012-08-01
WO2008024484A1 (en) 2008-02-28
CN104306977A (zh) 2015-01-28
JP6053279B2 (ja) 2016-12-27
RS52956B (sr) 2014-02-28
JP2022185091A (ja) 2022-12-13
PL2478907T3 (pl) 2021-10-25
IL257681A (en) 2018-04-30
HK1131577A1 (en) 2010-01-29
JP2017052791A (ja) 2017-03-16
AU2015221447A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
CY1124221T1 (el) Συνθεσεις για τη θεραπεια του καρκινου
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
Mihailidou et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction
ID26781A (id) Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer
WO2010081032A3 (en) Steroidal compositions
Chetrite et al. The selective estrogen enzyme modulator (SEEM) in breast cancer
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
IN2012DN04867A (pl)
MXPA06000326A (es) Novedosos compuestos y composiciones que contienen esteroles y/o estanoles e inhibidores de biosintesis de colesterol, y su uso en el tratamiento o prevencion de una variedad de enfermedades y condiciones.
Xiong et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
Dhondt et al. Abiraterone and spironolactone in prostate cancer: a combination to avoid
Xi et al. Effects of low concentrations of di-(2-ethylhexyl) and mono-(2-ethylhexyl) phthalate on steroidogenesis pathways and apoptosis in the murine leydig tumor cell line MLTC-1
Wang et al. Nicotine induced CpG methylation of Pax6 binding motif in StAR promoter reduces the gene expression and cortisol production
PT1526856E (pt) Composição farmacêutica que compreende derivados do estretol para ser utilizada no tratamento do cancro
MX391234B (es) Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas.
CY1105607T1 (el) Η χρηση ενος η1 ανταγωνιστη και ριμεξαολης ως ενα ασφαλες στεροειδες για την θεραπεια ρινιτιδας
Agarwal et al. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
TR200101766T2 (tr) Dehidroepiandrosteronun klatratları ve bunlara tekabül eden kompozisyonlar
Fiandalo et al. Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
Brueggemeier Aromatase inhibitors: new endocrine treatment of breast cancer
Dank The role of aromasin in the hormonal therapy of breast cancer
AR089839A1 (es) Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular
Aragon-Ching et al. Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application